Andrew E. Levitt

Andrew is an associate in Taft’s Intellectual Property group. His practice includes patent prosecution, invalidity, and non-infringement opinions; prior art, clearance, and freedom-to-operate searches; as well as patent landscape studies, with a focus on biological sciences, pharmaceutical sciences, biochemistry, and biomedical instruments and methods. He also has experience handling clearance matters, as well as intellectual property transactions and licensing.

Prior to joining Taft, Andrew worked as patent counsel in the New York office of a well-known international firm.

Andrew earned his J.D. from William & Mary Law School where he graduated in the top 20% and was an articles editor for the William & Mary Bill of Rights Journal and the vice president of the Student Intellectual Property Society. He also completed research on lipid metabolism at Johns Hopkins University and earned his bachelor’s degree in biological sciences from George Washington University.

• Co-author, “Amgen v. Sanofi: Seven Months In, Has Anything About Patent Enablement Changed?” IPWatchdog, Jan. 9, 2023. (with Ryan Hiler)